CPRIT awards more than $93M for cancer research and prevention

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

On May 21, the governing body of the Cancer Prevention and Research Institute of Texas approved 61 grants totaling more than $93 million. The grants support cancer research and prevention projects across the entire spectrum of CPRIT’s mission, including CPRIT Scholar recruitment grants, a wide array of evidence-based prevention programs, and funding for early-stage companies developing promising new treatments for cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Patients saw a 35% reduced risk of disease progression or death for Trodelvy (sacituzumab govitecan-hziy) plus Keytruda (pembrolizumab) (n=221) versus standard of care Keytruda plus chemotherapy (n=222), according to the positive phase III ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy plus Keytruda in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login